MAXON and MAXON CV synthetic absorbable sutures are prepared from polyglyconate, a copolymer of glycolic acid and trimethylene carbonate MAXON and MAXON CV synthetic absorbable sutures are indicated for use in general soft tissue approximation and/or ligation, including use in pediatric cardiovascular tissue, where growth is expected to occur, and in peripheral vascular surgery MAXON and MAXON CV synthetic absorbable sutures are not indicated for use in adult cardiovascular tissue, ophthalmic surgery, microsurgery and neural tissues MAXON sutures retain approximately 75% of initial tensile strength at two weeks, 65% of at three weeks and 50% at four weeks post-implant Absorption of MAXON sutures is minimal until about 60 days after implant and is essentially complete within six months This product is required to be reported under California Proposition 65